Logo image of LLY.DE

ELI LILLY & CO (LLY.DE) Stock Fundamental Analysis

FRA:LLY - Deutsche Boerse Ag - US5324571083 - Common Stock - Currency: EUR

663.1  -15.5 (-2.28%)

Fundamental Rating

6

LLY gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. LLY has an excellent profitability rating, but there are some minor concerns on its financial health. LLY is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

9

1. Profitability

1.1 Basic Checks

In the past year LLY was profitable.
LLY had a positive operating cash flow in the past year.
Each year in the past 5 years LLY has been profitable.
Each year in the past 5 years LLY had a positive operating cash flow.
LLY.DE Yearly Net Income VS EBIT VS OCF VS FCFLLY.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

1.2 Ratios

LLY's Return On Assets of 12.42% is amongst the best of the industry. LLY outperforms 84.00% of its industry peers.
LLY has a better Return On Equity (70.45%) than 94.00% of its industry peers.
LLY has a Return On Invested Capital of 27.17%. This is amongst the best in the industry. LLY outperforms 94.00% of its industry peers.
The Average Return On Invested Capital over the past 3 years for LLY is significantly above the industry average of 14.77%.
The 3 year average ROIC (21.71%) for LLY is below the current ROIC(27.17%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROIC 27.17%
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
LLY.DE Yearly ROA, ROE, ROICLLY.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

With an excellent Profit Margin value of 22.66%, LLY belongs to the best of the industry, outperforming 82.00% of the companies in the same industry.
In the last couple of years the Profit Margin of LLY has declined.
The Operating Margin of LLY (40.25%) is better than 94.00% of its industry peers.
LLY's Operating Margin has improved in the last couple of years.
The Gross Margin of LLY (81.70%) is better than 80.00% of its industry peers.
In the last couple of years the Gross Margin of LLY has remained more or less at the same level.
Industry RankSector Rank
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
LLY.DE Yearly Profit, Operating, Gross MarginsLLY.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so LLY is creating value.
LLY has about the same amout of shares outstanding than it did 1 year ago.
LLY has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, LLY has a worse debt to assets ratio.
LLY.DE Yearly Shares OutstandingLLY.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
LLY.DE Yearly Total Debt VS Total AssetsLLY.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B

2.2 Solvency

An Altman-Z score of 7.73 indicates that LLY is not in any danger for bankruptcy at the moment.
LLY's Altman-Z score of 7.73 is amongst the best of the industry. LLY outperforms 94.00% of its industry peers.
LLY has a Debt/Equity ratio of 2.19. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.19, LLY is doing worse than 78.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Altman-Z 7.73
ROIC/WACC2.78
WACC9.77%
LLY.DE Yearly LT Debt VS Equity VS FCFLLY.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10B 20B

2.3 Liquidity

A Current Ratio of 1.37 indicates that LLY should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.37, LLY is in line with its industry, outperforming 54.00% of the companies in the same industry.
LLY has a Quick Ratio of 1.06. This is a normal value and indicates that LLY is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of LLY (1.06) is better than 64.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.06
LLY.DE Yearly Current Assets VS Current LiabilitesLLY.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

8

3. Growth

3.1 Past

LLY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.01%, which is quite impressive.
The Earnings Per Share has been growing by 16.57% on average over the past years. This is quite good.
LLY shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.38%.
The Revenue has been growing by 15.08% on average over the past years. This is quite good.
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%

3.2 Future

LLY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.28% yearly.
Based on estimates for the next years, LLY will show a quite strong growth in Revenue. The Revenue will grow by 17.46% on average per year.
EPS Next Y68.06%
EPS Next 2Y50.91%
EPS Next 3Y41.6%
EPS Next 5Y30.28%
Revenue Next Year32.22%
Revenue Next 2Y25.41%
Revenue Next 3Y22.39%
Revenue Next 5Y17.46%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
LLY.DE Yearly Revenue VS EstimatesLLY.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20B 40B 60B 80B 100B
LLY.DE Yearly EPS VS EstimatesLLY.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 55.82, the valuation of LLY can be described as expensive.
Compared to the rest of the industry, the Price/Earnings ratio of LLY indicates a slightly more expensive valuation: LLY is more expensive than 64.00% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of LLY to the average of the S&P500 Index (27.50), we can say LLY is valued expensively.
Based on the Price/Forward Earnings ratio of 25.93, the valuation of LLY can be described as expensive.
64.00% of the companies in the same industry are cheaper than LLY, based on the Price/Forward Earnings ratio.
LLY is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.44, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 55.82
Fwd PE 25.93
LLY.DE Price Earnings VS Forward Price EarningsLLY.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

72.00% of the companies in the same industry are cheaper than LLY, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 36.19
LLY.DE Per share dataLLY.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LLY has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as LLY's earnings are expected to grow with 41.60% in the coming years.
PEG (NY)0.82
PEG (5Y)3.37
EPS Next 2Y50.91%
EPS Next 3Y41.6%

More info and screens

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.79%, LLY is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 3.04, LLY has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.34, LLY's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.79%

5.2 History

The dividend of LLY is nicely growing with an annual growth rate of 15.60%!
Dividend Growth(5Y)15.6%
Div Incr Years6
Div Non Decr Years6
LLY.DE Yearly Dividends per shareLLY.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3 4 5

5.3 Sustainability

LLY pays out 43.74% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of LLY is growing, but earnings are growing more, so the dividend growth is sustainable.
DP43.74%
EPS Next 2Y50.91%
EPS Next 3Y41.6%
LLY.DE Yearly Income VS Free CF VS DividendLLY.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B 6B 8B 10B
LLY.DE Dividend Payout.LLY.DE Dividend Payout, showing the Payout Ratio.LLY.DE Dividend Payout.PayoutRetained Earnings

More info and screens

ELI LILLY & CO

FRA:LLY (7/18/2025, 7:00:00 PM)

663.1

-15.5 (-2.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners83.95%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap628.45B
Analysts81.21
Price Target849.9 (28.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.79%
Yearly Dividend4.24
Dividend Growth(5Y)15.6%
DP43.74%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.92%
Min EPS beat(2)6.45%
Max EPS beat(2)9.38%
EPS beat(4)3
Avg EPS beat(4)11.23%
Min EPS beat(4)-20.34%
Max EPS beat(4)49.43%
EPS beat(8)7
Avg EPS beat(8)29.89%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)11
Avg EPS beat(16)14.81%
Revenue beat(2)0
Avg Revenue beat(2)-0.87%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)-0.5%
Revenue beat(4)1
Avg Revenue beat(4)1.15%
Min Revenue beat(4)-6.46%
Max Revenue beat(4)12.82%
Revenue beat(8)4
Avg Revenue beat(8)2.39%
Revenue beat(12)5
Avg Revenue beat(12)0.98%
Revenue beat(16)9
Avg Revenue beat(16)1.3%
PT rev (1m)-1.57%
PT rev (3m)-9.59%
EPS NQ rev (1m)0.44%
EPS NQ rev (3m)0.74%
EPS NY rev (1m)0.04%
EPS NY rev (3m)-6.66%
Revenue NQ rev (1m)1.35%
Revenue NQ rev (3m)1.79%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)0.15%
Valuation
Industry RankSector Rank
PE 55.82
Fwd PE 25.93
P/S 14.85
P/FCF N/A
P/OCF 78.1
P/B 46.16
P/tB 182.74
EV/EBITDA 36.19
EPS(TTM)11.88
EY1.79%
EPS(NY)25.57
Fwd EY3.86%
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)8.49
OCFY1.28%
SpS44.65
BVpS14.37
TBVpS3.63
PEG (NY)0.82
PEG (5Y)3.37
Profitability
Industry RankSector Rank
ROA 12.42%
ROE 70.45%
ROCE 33.25%
ROIC 27.17%
ROICexc 28.73%
ROICexgc 36.37%
OM 40.25%
PM (TTM) 22.66%
GM 81.7%
FCFM N/A
ROA(3y)11.42%
ROA(5y)11.8%
ROE(3y)60.64%
ROE(5y)70.77%
ROIC(3y)21.71%
ROIC(5y)19.96%
ROICexc(3y)23.23%
ROICexc(5y)21.74%
ROICexgc(3y)32.89%
ROICexgc(5y)32.31%
ROCE(3y)29.19%
ROCE(5y)26%
ROICexcg growth 3Y1.59%
ROICexcg growth 5Y4.02%
ROICexc growth 3Y9.55%
ROICexc growth 5Y8.81%
OM growth 3Y12.38%
OM growth 5Y7.84%
PM growth 3Y6.05%
PM growth 5Y-8.8%
GM growth 3Y3.11%
GM growth 5Y0.62%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF N/A
Debt/EBITDA 1.6
Cap/Depr 578.92%
Cap/Sales 21.61%
Interest Coverage 250
Cash Conversion 43.23%
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.06
Altman-Z 7.73
F-Score6
WACC9.77%
ROIC/WACC2.78
Cap/Depr(3y)374.28%
Cap/Depr(5y)279.43%
Cap/Sales(3y)16.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.01%
EPS 3Y16.75%
EPS 5Y16.57%
EPS Q2Q%29.46%
EPS Next Y68.06%
EPS Next 2Y50.91%
EPS Next 3Y41.6%
EPS Next 5Y30.28%
Revenue 1Y (TTM)36.38%
Revenue growth 3Y16.73%
Revenue growth 5Y15.08%
Sales Q2Q%45.17%
Revenue Next Year32.22%
Revenue Next 2Y25.41%
Revenue Next 3Y22.39%
Revenue Next 5Y17.46%
EBIT growth 1Y73.83%
EBIT growth 3Y31.18%
EBIT growth 5Y24.1%
EBIT Next Year83.18%
EBIT Next 3Y42.52%
EBIT Next 5Y29.3%
FCF growth 1Y-133.54%
FCF growth 3Y-57.48%
FCF growth 5Y-34.68%
OCF growth 1Y36.68%
OCF growth 3Y6.69%
OCF growth 5Y12.76%